Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection

Rapid improvements in hepatitis C virus (HCV) therapy have led to the approval of multiple oral direct-acting antiviral (DAA) regimens by the U.S. Food and Drug Administration (FDA) for treatment of chronic HCV infection.To summarize published literature on the efficacy and safety of oral DAAs for treatment of persons with chronic HCV infection.MEDLINE and EMBASE from inception through 1 November 2016.42 English-language studies from controlled...